TGFB1 and nonpapillary renal cell carcinoma: The downregulation of TGF-β1 may increase the efficacy of TKIs and ICIs when used together in ccRCC treatments possibly by preventing the development of treatment resistance mechanisms facilitated by high levels of TGF-β1.